GENMAB A/S -SP ADR

GMAB represents Genmab A/S, a biotechnology company focused on developing antibody therapeutics for cancer and other serious diseases. Its portfolio includes marketed medicines and a pipeline of investigational compounds created through proprietary antibody technologies. GMAB generates revenue from product sales, royalties, and collaboration agreements with partners. The company operates globally, with research and development activities aimed at addressing unmet medical needs. Because GMAB is a biotech, its business depends on clinical trial outcomes, regulatory approvals, and commercialization success.

GMAB is listed on the Nasdaq Global Select Market in the United States. Genmab A/S, the company behind GMAB, is also listed on Nasdaq Copenhagen under the ticker GMAB. The U.S. listing allows investors to trade GMAB shares during regular U.S. market hours. For the most current listing details, trading venue information, and any changes, refer to the GMAB stock page displayed on this platform.

The current price of GMAB stock changes throughout the trading day based on supply and demand. For the latest live quote, please check the GMAB stock page on this platform, which shows the most recent price, daily change, and other market data. Providing a specific number here could be outdated or inaccurate.

GMAB's volatility is influenced by its biotech focus, clinical trial news, regulatory decisions, and broader market conditions. Biotech stocks can experience sharper price swings than diversified companies, especially around data readouts or partnership announcements. Volatility may also rise with changes in interest rates or sector sentiment. For historical volatility measures such as beta or standard deviation, check the latest GMAB data provided on this page.

Evaluating GMAB's valuation typically involves comparing its market capitalization, price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value to peers in the biotechnology sector. Because biotech earnings can be volatile, analysts often use pipeline-based or revenue-multiple approaches. You can find GMAB's current valuation metrics on the stock detail page. Consider both the company's growth prospects and the risks inherent in drug development.

Key risks for GMAB include clinical trial failures, regulatory delays or rejections, competition from other therapies, and dependence on key products or partnerships. As a biotech, GMAB faces high research and development costs and potential intellectual property challenges. Broader market, economic, and interest rate changes can also affect its stock. Investors should review GMAB's risk factors in its annual reports and monitor pipeline updates.